Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · IEX Real-Time Price · USD
39.91
+0.09 (0.23%)
At close: May 3, 2024, 4:00 PM
40.69
+0.78 (1.95%)
After-hours: May 3, 2024, 7:37 PM EDT
Halozyme Therapeutics Employees
Halozyme Therapeutics had 373 employees on December 31, 2023. The number of employees decreased by 20 or -5.09% compared to the previous year.
Employees
373
Change (1Y)
-20
Growth (1Y)
-5.09%
Revenue / Employee
$2,223,198
Profits / Employee
$754,944
Market Cap
5.07B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 373 | -20 | -5.09% |
Dec 31, 2022 | 393 | 248 | 171.03% |
Dec 31, 2021 | 145 | 9 | 6.62% |
Dec 31, 2020 | 136 | 4 | 3.03% |
Dec 31, 2019 | 132 | -149 | -53.02% |
Dec 31, 2018 | 281 | 26 | 10.20% |
Dec 31, 2017 | 255 | -4 | -1.54% |
Dec 31, 2016 | 259 | 43 | 19.91% |
Dec 31, 2015 | 216 | 63 | 41.18% |
Dec 31, 2014 | 153 | -17 | -10.00% |
Dec 31, 2013 | 170 | 18 | 11.84% |
Dec 31, 2012 | 152 | 17 | 12.59% |
Dec 31, 2011 | 135 | 33 | 32.35% |
Dec 31, 2010 | 102 | -38 | -27.14% |
Dec 31, 2009 | 140 | 10 | 7.69% |
Dec 31, 2008 | 130 | 38 | 41.30% |
Dec 31, 2007 | 92 | 52 | 130.00% |
Dec 31, 2006 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
R1 RCM | 30,000 |
Bausch + Lomb | 13,300 |
Organon & Co. | 10,000 |
Option Care Health | 7,802 |
Haemonetics | 3,034 |
Glaukos | 907 |
Lantheus Holdings | 834 |
BridgeBio Pharma | 550 |
HALO News
- 10 days ago - Mahesh Krishnan Elected to Halozyme's Board of Directors - PRNewsWire
- 12 days ago - Halozyme to Report First Quarter 2024 Financial and Operating Results - PRNewsWire
- 2 months ago - Halozyme to Participate in Upcoming Investor Conferences - PRNewsWire
- 2 months ago - HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS - PRNewsWire
- 3 months ago - Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results - PRNewsWire
- 3 months ago - Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - PRNewsWire
- 3 months ago - Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis - PRNewsWire
- 3 months ago - Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - PRNewsWire